IRIDEX Corporation (IRIX) Analysts See $-0.33 EPS

April 17, 2018 - By Christine McCrea

IRIDEX Corporation (NASDAQ:IRIX) LogoInvestors sentiment increased to 1.2 in Q4 2017. Its up 0.65, from 0.55 in 2017Q3. It improved, as 5 investors sold IRIDEX Corporation shares while 5 reduced holdings. 1 funds opened positions while 11 raised stakes. 5.52 million shares or 2.07% less from 5.63 million shares in 2017Q3 were reported.
Northern Trust owns 58,299 shares for 0% of their portfolio. 37,581 are held by Finemark State Bank And Trust. Renaissance Technology Limited Liability Corp has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). 500 were reported by Thompson Davis & Inc. Blackrock holds 28,161 shares. Vanguard Group holds 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX) for 397,522 shares. Dimensional Fund Lp accumulated 201,395 shares. Massachusetts-based Geode Cap Mngmt Ltd Liability Co has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). Millennium Mngmt Llc holds 58,412 shares or 0% of its portfolio. Perkins Mngmt Incorporated reported 0.39% in IRIDEX Corporation (NASDAQ:IRIX). First Light Asset Mgmt Lc reported 317,799 shares. Lyon Street Capital Ltd Liability Corporation has invested 1.23% in IRIDEX Corporation (NASDAQ:IRIX). California Employees Retirement System has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). Neuberger Berman Llc invested in 15,000 shares or 0% of the stock. Manufacturers Life The holds 0% of its portfolio in IRIDEX Corporation (NASDAQ:IRIX) for 814 shares.

Since December 12, 2017, it had 1 buying transaction, and 1 sale for $22,756 activity. The insider MOORE WILLIAM M bought $39,200.

Analysts expect IRIDEX Corporation (NASDAQ:IRIX) to report $-0.33 EPS on May, 2.They anticipate $0.17 EPS change or 106.25 % from last quarter’s $-0.16 EPS. After having $-0.44 EPS previously, IRIDEX Corporation’s analysts see -25.00 % EPS growth. The stock decreased 2.04% or $0.12 during the last trading session, reaching $5.76. About 18,357 shares traded. IRIDEX Corporation (NASDAQ:IRIX) has declined 53.54% since April 17, 2017 and is downtrending. It has underperformed by 65.09% the S&P500.

IRIDEX Corporation provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company has market cap of $66.97 million. The firm offers laser consoles, such as Cyclo G6 laser system used for the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It currently has negative earnings. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physicians to perform multi-spot pattern scanning; Slit Lamp Adapter, which allows the physicians to utilize a standard slit lamp in diagnosis and treatment procedures; and TruFocus laser indirect ophthalmoscopes for use in procedures to treat peripheral retinal disorders.

IRIDEX Corporation (NASDAQ:IRIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: